Brief: XSpray Pharma Gets Approval From Swedish MPA
June 21 (Reuters) - XSPRAY PHARMA AB (PUBL) XSPRAY.ST :
* XSPRAY PHARMA GETS GO-AHEAD FROM THE SWEDISH MPA FOR
CLINICAL
STUDY
* GETS APPROVAL FROM SWEDISH MEDICAL PRODUCTS AGENCY TO
CARRY OUT
CLINICAL STUDY OF PRODUCT CANDIDATE HYNAP-DASA
Source text for Eikon: ID:nWkr31TnPG
Further company coverage: XSPRAY.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003